After eight years, Macro Polo has ceased operations as the Paulson Institute will focus its independent research on supporting its programs as it continues to diversify its scope.
We appreciate the community that has grown around Macro Polo and the fruitful engagement we’ve had with our legion of smart and sharp audience. You’ve pushed us to deliver even more original work and innovative products. Our body of work speaks for itself, and we hope it will have a long shelf life – that was the intent from MP’s inception.
MP’s website is now archived and no new work will be published henceforth on this site. Please visit www.paulsoninstitute.org for future research and policy work on a range of global issues.
Thank you all for the support over the years, it has been a privilege to have had a home at the Paulson Institute and to have built it the way we did.
- Team Macro Polo
As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Huapont Life Sciences has three main business lines, including pharmaceuticals, pesticides, and active pharmaceutical ingredients (APIs). The company manufactures dermatology, tuberculosis, and cancer treatment drugs. Its pesticide business involves the production and sale of herbicides, including NC36, NC125, NC201, NC34, and NC16. Its API business centers on supplying bulk pharmaceutical chemicals, intermediates, and preparing Chinese and Western medicines.
Zhang Songshan
Chongqing
(023) 6788.6900
Huapont@163.com
In August 2014, Huapont Life Sciences invested $220 million for a 15% stake in Albaugh, one of the largest generic agro-chemical manufacturers in the United States. In July 2016, Huapont Life Sciences entered into an equity and license agreement with Angionetics, a cardiovascular firm in California, investing $3 million for 15% of preferred stock. The investment will support the clinical development of a heart disease therapy.
In December 2015, Huapont acquired a 69.84% stake in Swiss Biological Medicine company for $30.4 million.